Environmental monitoring
Prediction of contamination by analyzing seasonal and operational trends, mitigating risk before microbiological plating.
Quality 4.0 & Compliance ANVISA
AI in Pharmaceutical Quality: the future of Predictive GMP
We transform reactive operations into regulatory intelligence centers. We implement AI models for data integrity, deviation management and continuous compliance with ANVISA, PIC/S and GMP.
AccreditationANVISA / GMP / PIC/S
Typical result−40% compliance risks
FrameworkGAMP 5 · ALCOA+
Operational scenario
The exhaustion of reactive models.
Quality Assurance based on manual log review and late detection of deviations does not keep up with the speed of global pharmaceutical chains nor the maturity required by modern inspections. The regulatory paradigm migrates from containment to anticipation.
Regulatory complexity
Harmonization PIC/S and RDC 658/2022 require continuous monitoring, not just retrospective.
GMP data volume
Sensors, MES and LIMS generate data beyond human ability to analyze — risk of Data Rich, Information Poor.
Pressure for efficiency
Increasingly shorter deviation investigation cycles under increasing audit scrutiny.
Accelerated scanning
Quality 4.0 stops being a differentiator and becomes a regulated competitive prerequisite.
GMP/GMP Applications
AI applied to the regulated factory floor.
↓
Predictive deviation analysis
Identification of subtle patterns in processes that precede OOS and OOT, before the batch is committed.
Document review (NLP)
Automated checking of Batch Records, protocols and technical logs against inconsistencies and ALCOA+ violations.
Deviation management and CAPA
Automatic clustering of occurrences and systemic root cause suggestion for effective corrective actions.
Continuous environmental control
Integration with HVAC, WFI and cleanrooms for real-time failure prediction and regulatory impact.
Trend and risk analysis
Advanced statistical models for Periodic Product Review and integrated quality risk management (ICH Q9).
Digital maturity
From reactive quality to predictive quality.
Regulatory competitive advantage is not just compliance, but the ability to anticipate risks before they materialize into deviations, non-conformities or inspection observations.
Current scenario
Manual analyses, data silos, and weeks-long deviation investigations.
Digital maturity
Continuous real-time monitoring with predictive alerts based on validated machine learning.
| Dimension | Traditional | With AI |
|---|---|---|
| Deviation management | Post-occurrence investigation | Real-time pattern detection |
| Data integrity | Sampling verification | 100% automated audit (ALCOA+) |
| Monitoring | Periodic Snapshots | Continuous Process Verification (CPV) |
| Compliance | Reactive to audits | Audit-readiness permanente |
| CAPA | Specific corrective actions | Systemic root cause elimination |
ANVISA regulatory roadmap
AI in Manufacturing 2026: ANVISA’s new roadmap.
ANVISA adopts international regulatory convergence (PIC/S and ICH) for 2026, focusing on Annex 22: AI in critical environments must be controllable, testable and predictable.
Schedule 22 Golden Rules
Mandatory technical standards
Static and deterministic models
Mandatory for critical applications that impact patient safety and product quality.
Prohibition of dynamic models
Systems that continuously learn in production are prohibited to avoid parameter drift.
Generative AI and LLMs under Constraint
Use permitted only in non-critical contexts and under Human in the Loop (HITL) regime.
Governance, validation and compliance
Transparency requirements
Risk management (ICH Q9)
Every AI implementation must follow rigorous validation and continuous performance monitoring.
End of the black box
Explainability is required to record which characteristics contributed to a decision or batch classification.
Full data independence
Test data for validation must be technically separate from the data used in training.
Framework 2026
Criticality comparison for the use of AI
| AI application | Regulatory status | Main requirement |
|---|---|---|
| Criticism (BPF) | Allowed (static only) | Absolute determinism and high reproducibility |
| Criticism (dynamic) | Prohibited | Unacceptable risk of process instability |
| Non-critical (GenAI) | Allowed | Mandatory supervision by qualified personnel (HITL) |
AI & Regulatory Compliance
Strengthening compliance, without replacing the specialist.
AI does not dilute regulatory responsibility, it expands it. It acts as a layer of digital evidence, providing QA, QC, Validation and Regulatory Affairs teams with the necessary analytical support for defensible decisions before health authorities.
Data integrity
ALCOA+ applied on an automated scale over LIMS, MES and SCADA.
Traceability
Immutable, contextualized audit trails in real time.
Audit-readiness
Continuous preparation for ANVISA, FDA and EMA inspections.
Regulatory governance
Policies, roles and formal controls over the model lifecycle.
GMP / BPF / PIC/S
Adherence to RDC 658/2022 and harmonized international guides.
Quality culture
Data-driven decisions across the entire regulated operation.
The biggest challenge
AI without adequate structure is a regulatory risk.
Unstructured implementations generate compliance liabilities. We first work on the base/data, governance, processes and culture, so that AI operates predictably within the GMP perimeter.
Data quality
Without reliable data, predictive models amplify noise rather than generating regulatory value.
Governance
Model lifecycle requires formalized policies, roles, and change control.
Process maturity
Unstable processes make it difficult to distinguish natural variation from real deviation.
Organizational culture
Adoption requires data literacy across the entire quality chain — not just IT.
Positioning
AI does not replace experts, it empowers them.
The final decision in a GMP environment will always be human. Our consultancy structures how QA, QC, Validation and Regulatory Affairs teams can use AI as a precision tool — removing operational burden and increasing focus on strategy, risk and patient safety.
The future
Data-driven pharmaceutical quality.
The next regulatory cycle will reward connected, predictable and auditable operations in real time. Digital maturity becomes a direct indicator of competitiveness.
Technical authority
Consulting specialized in regulated pharmaceutical quality.
Combined action of experts in GMP/GMP, ANVISA compliance and data scientists applied to GxP systems. Regulatory depth, not experimentation.
T&B Pharma Consulting
We can help with projects involving AI with Data Integrity.
Specialized consultancy for the future of the pharmaceutical industry. Our mission is to do the best in GMP concepts — structuring AI projects that are born already compliant with Annex 22, ALCOA+ and the PIC/S and ICH regulatory convergence.
We work from diagnosing digital maturity to validating computerized systems (CSV/CSA, GAMP 5), model governance and preparation for ANVISA, FDA and EMA inspections.
Technical diagnosis
Assess the digital maturity of your quality.
Schedule a technical meeting with our GMP and Artificial Intelligence experts. Receive consultative analysis on regulatory risks, AI opportunities and digital quality transformation roadmap.
Data IntegrityANVISA ComplianceGMP ExcellenceSPORT 5
Regulatory FAQ
FAQs about AI in pharmaceutical quality.
How does AI ensure data integrity (ALCOA+) in GMP environments?
+
The models act as a supervisory layer over LIMS, MES and SCADA systems, monitoring audit trails in real time and detecting retroactive edits, unauthorized deletions or metadata inconsistencies, preserving the Attributable, Legible, Contemporaneous, Original and Accurate principles without manual intervention.
Does ANVISA accept validations based on Machine Learning?
+
Yes, as long as the system follows the principles of Computerized Systems Validation (CSV/CSA) and the GAMP 5 2nd Edition framework, with formal change control, risk-based qualification and continuous monitoring of model performance (model drift).
How is AI applied to investigation of deviations and CAPA?
+
Clustering algorithms identify systemic patterns between apparently isolated occurrences, suggesting root causes and prioritizing corrective actions with a greater probability of effectiveness, reducing recurrence and the investigation cycle.
What is the impact of AI on regulatory audits?
+
The audit is no longer based on snapshots and starts to operate continuously. The result is permanent audit-readiness, with a significant reduction in preparation time for ANVISA, FDA and EMA inspections.
Does AI replace the Quality Assurance team?
+
No. AI acts as a precision tool. The final regulatory decision in GMP environments is always human. The role of computational intelligence is to remove the burden of manual processing and expand the specialist's analytical capacity.
What is the average implementation time for a project?
+
Digital maturity diagnosis projects last around 4 weeks. Implementations of specific modules (e.g.: Periodic Digital Product Review, predictive environmental monitoring) take 3 to 6 months, depending on the existing data infrastructure.